Feighner 1989.

Methods	Six‐week double‐blind, randomised, parallel group, single‐centre, placebo‐controlled study.
Participants	Outpatients meeting DSM‐III criteria for major depression with a minimum score of 18 on Hamilton rating scale for depression (HDRS‐17). Age: older than 18 years.
Interventions	Paroxetine: 40 participants. Imipramine: 40 participants. Placebo: 40 participants. Paroxetine dose range: 10‐50 mg/day. Imipramine dose range: 65‐275 mg/day.
Outcomes	HDRS‐21, Clinical Global Impression (CGI) Improvement, Severity, Montgomery and Asberg Depression Rating Scale (MADRS), Patient Global Experience (PGE). Total dropout, dropout due to side effect, dropout due to lack of efficacy. Number of patients experiencing at least one side effect, side‐effect profile.
Notes	Funding: paroxetine manufacturer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	Study endpoint: 19/40 missing from paroxetine group, 26/40 missing from control group.
Selective reporting (reporting bias)	High risk	Dichotomous outcome not reported.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.